NFKB1 and lymphoma: On the basis of these results, pelabresib (previously known as CPI-0610) has potential antitumor activity, particularly in heavily pretreated patients with NF-kB-driven relapse/refractory lymphoma, at doses below the MTD with clear BET-driven target suppression and appeared to have an acceptable safety profile.